Diabetes drugs Archives

Eli Lilly deals another blow to diabetes with latest FDA approval

Approvals, Chronic Diseases, Diabetes, Diabetes, Diabetes, Diabetes drugs, Eli Lilly, FDA, Glucagon, Glucagon-Like Peptide-1 (GLP-1) Analogs, Peptide Hormones, Therapeutics, Type 2 Diabetes

Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.

May 16, 2022/by BioSpace

Eli Lilly’s lucrative Q1 2022 driven by Trulicity and COVID-19 antibodies

Alzheimer’s disease, Bamlanivimab (LY-CoV555), Bebtelovimab (LY-CoV1404; LY3853113), Business, COVID-19 Antibodies, Diabetes, Diabetes drugs, Earnings per share (EPS), Eli Lilly, Etesevimab (Lilly), Financials, Forecasts, Obesity, Obesity, Sales, Therapeutics, Trulicity

Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.

April 28, 2022/by BioSpace